全程静脉腔内激光消融多中心试验早期结果
TOTEM试验为前瞻性多中心非随机研究,纳入153例CEAP C2-C6患者,单次会话行全程静脉腔内激光消融(TEVLA)治疗主干、属支和穿通静脉。7天闭塞率99.3%,6个月98.3%,无深静脉血栓或热诱导血栓事件,rVCSS显著改善。
要点
- TEVLA单次会话闭塞率7天99.3%、6个月98.3%。
- 无深静脉血栓或热诱导血栓事件,轻微并发症低。
- rVCSS 1个月平均改善-3.24(P < .001)。
核心结论
- TEVLA是安全有效的单步技术,闭塞率高、并发症率低,需进一步随机研究。
研究设计与样本
- 前瞻性多中心非随机研究,纳入153例CEAP C2-C6患者。
主要发现
- 闭塞率7天99.3%,6个月98.3%。
- 无深静脉血栓或热诱导血栓事件。
- 轻微并发症包括色素沉着5.9%和感觉异常2.6%。
- rVCSS 1个月平均显著改善-3.24(P < .001)。
- 线性静脉腔内能量密度与并发症无关联。
关键数值与推荐
- 主要终点为闭塞率。
- 次要终点包括并发症、疼痛(VAS)和rVCSS改善。
临床怎么用
- 可考虑单次会话TEVLA治疗主干、属支和穿通静脉。
局限性
- 非随机研究设计,需进一步随机研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety and efficacy of total endovenous laser ablation (TEVLA) in a multicenter cohort. METHODS: This prospective multicenter nonrandomized study included 153 patients (Clinical, Etiologic, Anatomic, Pathophysiologic Classification [CEAP] C2-C6). TEVLA was performed as a single-session procedure for the treatment of truncal veins, tributaries, and perforators. The primary end point was the occlusion rate. The secondary end points included complications, pain (visual analog scale [VAS]), and revised Venous Clinical Severity Score (rVCSS) improvement. RESULTS: The occlusion rate was 99.3% at 7 days and 98.3% at 6 months. No deep vein thrombosis or endothermal heat-induced thrombosis events were observed. Minor complications included hyperpigmentation (5.9%) and paresthesia (2.6%). The mean rVCSS significantly improved (-3.24 at 1 month; P < .001). No association was found between linear endovenous energy density and complications. CONCLUSIONS: TEVLA is a safe and effective single-step technique with high occlusion rates and low complication rates. Further randomized studies are warranted.
引用
- Palombi L, Szczepański J, Martinelli F, et al. Total Endovenous Laser Ablation Multicenter (TOTEM) trial: Early results. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42288158. doi:10.1016/j.jvsv.2026.102554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。